

**TEPEZZA  
(teprotumumab-trbw)****RATIONALE FOR INCLUSION IN PA PROGRAM****Background**

Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor (IGF-1R) injection, given via intravenous infusion. The mechanism of action has not been fully characterized but may be due to Tepezza binding to IGF-1R and blocking its activation and signaling (1).

**Regulatory Status**

FDA-approved indication: Tepezza is indicated for the treatment of Thyroid Eye Disease (1).

Tepezza may cause infusion reactions. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during any of the infusions or within 1.5 hours after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids and antihistamines. In patients who experience an infusion reaction, consideration should be given to pre-medicating with an antihistamine, antipyretic, corticosteroid, and/or administering all subsequent infusions at a slower infusion rate (1).

Patients treated with Tepezza should be monitored for elevated blood glucose and symptoms of hyperglycemia. Patients with pre-existing diabetes should be under appropriate glycemic control before receiving Tepezza (1).

The safety and effectiveness in pediatric patients less than 18 years of age have not been established (1).

**Summary**

Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor (IGF-1R) injection, given via intravenous infusion. The mechanism of action has not been fully characterized but may be due to Tepezza binding to IGF-1R and blocking its activation and signaling. The safety and effectiveness in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of



**BlueCross  
BlueShield**

Federal Employee Program.

**TEPEZZA**  
**(teprotumumab-trbw)**

Tepezza while maintaining optimal therapeutic outcomes.

**References**

1. Tepezza [package insert]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; July 2023.